

Cancer Trials that are due to become Active during June – August 2016

BREAST CANCER

Patients With	Study Name	Purpose of Study	Hospitals Taking Part
Metastatic HER2-Positive Breast Cancer	ICORG 15-02 / Panther	Study to assess copanlisib in combination with trastuzumab in pretreated recurrent or metastatic HER2-positive breast cancer	<u>Dublin</u> Beaumont, St Vincent's Galway University
(HR+)/HER2 Negative Early Breast Cancer	ICORG 15-17 / PALLAS	Study to assess palbociclib with adjuvant endocrine therapy versus endocrine therapy alone for hormone receptor positive (HR+)/HER2 negative early breast cancer	<u>Dublin</u> Beaumont, Mater, St James's, St Vincent's Cork University Galway University Waterford University
Endocrine Responsive Breast Cancer	ICORG 16-XX / POSITIVE	Study to evaluate the pregnancy outcomes and safety of interrupting endocrine therapy for young women with endocrine responsive breast cancer who desire pregnancy	To be confirmed

GYNAECOLOGY

Patients With	Study Name	Purpose of Study	Hospitals Taking Part
Advanced-Stage Platinum-Resistant /Refractory Ovarian Cancer	ICORG 15-22 / JAVELIN 200	Study of Avelumab alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in patients with advanced-stage platinum-resistant /refractory ovarian cancer	To be confirmed
Epithelial Ovarian Cancer	ICORG 16-05 / JAVELIN 100	Study to evaluate efficacy and safety of Avelumab in combination with and/or following chemotherapy in patients with previously untreated epithelial ovarian cancer	To be confirmed
HRD-Positive Advanced Ovarian Cancer	ICORG 16-04 / PRIMA	Study of Niraparib Maintenance Treatment in Patients with HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy	To be confirmed

HAEMATOLOGY & LYMPHOMA:

Patients With	Study Name	Purpose of Study	Hospitals Taking Part
Newly Diagnosed Treatment Naive Multiple Myeloma	ICORG 16-10 / KEYNOTE 185	Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab in Patients With Newly Diagnosed Treatment Naive Multiple Myeloma	<u>Dublin</u> Beaumont
Relapsed or Refractory Acute Myeloid Leukemia	ICORG 16-09 / 2215-CL-0301	Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation	To be confirmed
Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Low-Blast Acute Myelogenous Leukemia	ICORG 16-08 / P2001	Study to assess the Efficacy and Safety of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Low-Blast Acute Myelogenous Leukemia	To be confirmed
Myelodysplastic Syndrome	ICORG 15-36 / Onconova 04-03	Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA	To be confirmed

LUNG

Patients With	Study Name	Purpose of Study	Hospitals Taking Part
Non-Small Cell Lung Cancer	ICORG 15-47/INTENSE	INTENSE: Study of INhomogeneous Targeted Dose Escalation in Non-Small CELL Lung Cancer	<u>Dublin</u> St Luke's (SLRON)

Cancer Trials that are due to become Active during June – August 2016

MELANOMA

Patients With	Study Name	Purpose of Study	Hospitals Taking Part
Unresectable or Metastatic Melanoma	ICORG 16-13 / KEYNOTE 252	Study of Pembrolizumab + Epcadostat or Placebo in Patients With Unresectable or Metastatic Melanoma	Dublin Mater, St Vincent's Cork University Galway University
Advanced Melanoma	ICORG 16-14 / CHECKMATE 401	Study to assess Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma	Dublin Beaumont, Mater, St James's, St Vincent's Cork University Galway University

ALL CANCERS

Patients With	Study Name	Purpose of Study	Hospitals Taking Part
Melanoma	ICORG 15-42/Loxo-101	LOXO 101 Adult basket trial	St Vincent's